

Baxter

Revaclear

DESIGNED FOR:

OTHER APPLICABLE THERAPIES: **HFHD** (High flux) | **CONVECTIVE** (HDF)

MEMBRANE: **PORACTON** (PAES/PVP, BPA-free)

OPTIMIZING HIGH FLUX PERFORMANCE

The Revaclear dialyzer series is a range of high efficiency high-flux dialyzers designed to enhance safety and biocompatibility for your patients, while optimizing clearance with a smaller surface area.¹

OPTIMIZING PERFORMANCE FOR ALL YOUR PATIENTS²

The Revaclear dialyzers are designed to optimize the performance of high-flux treatments.

- The **Poracton** membrane provides effective permeability with minimal resistance to diffusion^{3,4,5}
- Three surface area options are available to meet individual patient needs
- Study in HD showed Revaclear 400 to remove small solutes and β_2 -microglobulin to a similar extent as a 22% larger surface area dialyzer²

WITH SAFETY AND **BIOCOMPATIBILITY IN MIND**

The relative compact surface area of the Revaclear dialyzers may help manage some patient risks.

- Reduces exposure of blood, potentially reducing clotting and micro inflammation⁶
- Produces less biohazardous waste and reduces saline need, compared to dialyzers of the same performance^{7,8}

Revaclear Specifications

MATERIALS	REVACLEAR 300	REVACLEAR 400	REVACLEAR 500	
Membrane	Delvezdethersul	Poracton fone and Polyvinyl		
	Polyarylethersul	BPA-free	pyrrolluone blenu	
Potting	I	Polyurethane (PUF	2]	
Housing		Polycarbonate (PC)		
Gaskets	Silicone rubber (SIR)			
Protection caps	Polypropylene (PP)			
Sterilization	Steam (inside-out)			
Sterile barrier		Tyvek		
SPECIFICATIONS				
UF-Coefficient (mL/(h*mmHg))*	48	54	65	
KoA urea*	1186	1439	1578	
Blood Compartment volume (mL)	74	93	106	
Minimum recommended		300		
priming volume (mL)		300		
Maximum TMP (mmHg)		600		
Recommended Q_B (mL/min)	200-500	200-600	250-600	
Storage conditions	<30°C (or <86°F)			
Units per box		24		
Gross/net weight (g)	215/160	225/170	250/190	
MEMBRANE				
Effective Membrane Area (m²)	1.4	1.8	2.1	
Fiber inner diameter (µm)		190		
Fiber wall thickness (µm)		35		
SIEVING COEFFICIENTS*				
Vitamin B12 (1,4 kDa)		1.0		

CLEARANCES IN VITRO (mL/min)*	REVACLEAR 300	REVACLEAR 400	REVACLEAR 500
Urea (60 Da) (Q _B -Q _D , mL/min)			
200-250**/500	196	198	244
300/500	272	281	284
400/500	323	338	345
400/800	355	369	375
500/800	408	430	439
Creatinine (113 Da)			
200-250**/500	191	195	238
300/500	256	267	272
400/500	298	315	323
400/800	330	348	355
500/800	373	398	409
Phosphate (142 Da)			
200-250**/500	185	191	230
300/500	242	255	261
400/500	278	297	306
400/800	309	330	338
500/800	345	373	384
Vitamin B12 (1.4 kDa)			
200-250**/500	146	158	183
300/500	174	191	200
400/500	191	213	223
400/800	212	236	247
500/800	228	256	269

** REVACLEAR 500

Vitamin B12 (1,4 kDa)	1.0
Inulin (5,2 kDa)	1.0
β ₂ -microglobulin (11,8 kDa)	0.95
Myoglobin (17 kDa)	0.68
Albumin (66,4 kDa)	0.0027

* According	to ISO 8637-1	

- UF-Coefficient: measured with bovine blood. Hct 32%, Pct 60g/L, 37°C

- KoA urea: calculated at Q_B =300 mL/min, Q_D =500mL/min, UF=0 mL/min

- Sieving coefficients: measured with human plasma, Q_B=300 mL/min, UF=60 mL/min

- Clearances In-Vitro: measured at UF=0 mL/min, ±10%

1 Baxter. REVACLEAR White Paper. USMP/MG3/140052, May 2013.

2. Mauric A, et al. Poster SP401, presented at 50th ERA-EDTA congress. Istanbul (Turkey), 2013.

Wand C., et al. Folder of the formed at obtained at output the EDFA congress. Island C. H. epiler, et al. Solution of synthetic membranes for bloch purification: the case of the Polyflux family. Nephrol Dial Transplant 2003;18[Suppl 7]:vii10-20.
Ward R, et al. Abstract SA-P0510, presented at the 40th ASN congress. San Francisco (USA), 2007.

Bhimani JP, et al. Effect of increasing dialysate flow rate on diffusive mass transfer of urea, phosphate and beta2-microglobulin during clinical haemodialysis. Nephrol Dial Transplant 2010; 25:3990-3995. 5.

Yao Q, et al. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int 2004; 8:118-129. 6. 7.

Baxter. Data on file. Biohazardous waste cost calculation, 2015.

8. Baxter. REVACLEAR dialyzer priming guide. 306150152_C, 2009.

Revaclear 300, Revaclear 400 and Revaclear 500 dialyzers are indicated for treatment of chronic & acute renal failure by Hemodialysis or Hemodiafiltration. The products meet the applicable provisions of Annex I (Essential Requirements) and Annex II (Full quality assurance system of the Council Directive 93/42/EEC of 14 June 1993, amended by Directive 2007/47/EC).

For safe and proper use of the device, please refer to the Instructions for Use

C€ 2797

Baxter, Poracton and Revaclear are trademarks of Baxter International Inc. or its subsidiaries.

GBU-RC38-200001 v1.0 - December 2020

MANUFACTURER Gambro Dialysatoren GmbH Holger-Crafoord-Strasse 26 72379 Hechingen Germany Baxter Healthcare Corporation One Baxter Parkway Deerfield, IL 60015 USA 1-800-422-9837